Hôpital Armand Trousseau, Service d’Hématologie-Immunologie Pédiatrique, 26 avenue du Dr Arnold Netter, 75012 Paris
Hôpital Robert Debré, Service d’hématologie-immunologie pédiatrique, Boulevard Sérurier, 75019 Paris
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. The identification of effective drug combination through collaborative international clinical trial has resulted in a steady improvement in treatment outcome. The identification of biological variables predictive of outcome and their use in stratifying treatment led to reduce the relapse risk. The current objectives are twofold; to improve the outcome for the significant minority of patients who relapse (with the development of target therapy and CAR-T cells) and to reduce the excessive drug toxicity (but maintain a high cure rate) for subgroups of patients with excellent outcome.
This work is licensed under a
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License